Anthony S. Marucci

Anthony S. Marucci (chief executive) discloses dealings in Celldex Therapeutics, Inc. to SEC (Form 4). Over a trading history stretching from 6 January 2009 to 11 November 2024, the count stands at 36 filings.

In open-market terms, that means 30 purchases worth €507k on one side and 1 sale worth €4.4M on the other. Netting one side against the other leaves €3.9M of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 1 share grant and 3 option exercises. Since January 2024: 1 purchase and no sales on the market.

The median purchase comes to €3,049. For 29 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 66% of cases, with a median move of +10.2%. They describe history only and say nothing certain about the share price ahead.

Most recently, on 12 November 2024, the filings show an open-market purchase worth €288k in Celldex Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.